Pharmacodynamic evaluation of the XOR inhibitor WN1703 in a model of chronic hyperuricemia in rats induced by yeast extract combined with potassium oxonate

Hyperuricemia is a common disease caused by a disorder of purine metabolism, which often causes hyperlipidemia and other metabolic diseases. WN1703 was demonstrated to be an effective xanthine oxidoreductase (XOR) inhibitor in our previous study. Here, we evaluated the pharmacodynamic effect of WN17...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuanyuan, Zhu, Xinying, Liu, Fuyao, Peng, Wen, Zhang, Lei, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026663/
https://www.ncbi.nlm.nih.gov/pubmed/35465446
http://dx.doi.org/10.1016/j.crphar.2022.100098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026663/
https://www.ncbi.nlm.nih.gov/pubmed/35465446
http://dx.doi.org/10.1016/j.crphar.2022.100098

Ejemplares similares